SIR-tainly a good performer..
SIR-tainly a good performer... Medical device group Sirtex (ASX: SRX) held its AGM this week. Sirtex's major product is SIR-Sphere - a treatment for liver cancer usually used in the final stages of cancer to prolong life expectancy. The company is currently undergoing trials for SIR-Sphere to be used at an earlier stage of liver cancer upon diagnosis, with results expected mid-2015. At the AGM, comments about the trial underway were positive and dose sales guidance was strong and ahead of market expectations, up 27% over the first four months of the financial year. SRX's share price has more than doubled in the last 12 months and closed up 10.0% this week. We own SRX in the investment portfolio.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Wilson Asset Management has a track record of making a difference for shareholders and the community for 25 years and is the investment manager for eight LICs - WAM Capital (ASX: WAM), WAM Leaders (ASX: WLE), WAM Global (ASX: WGB), WAM Microcap (ASX: WMI), WAM Alternative Assets (ASX: WMA), WAM Strategic Value (ASX: WAR), WAM Research (ASX: WAX) and WAM Active (ASX: WAA) - and the Wilson Asset Management Leaders Fund. Wilson Asset Management invests over $5 billion on behalf of more than 130,000 retail investors. Wilson Asset Management created and is the lead supporter of the first LICs to deliver both investment and social returns: Future Generation Australia (ASX: FGX) and Future Generation Global (ASX: FGG).
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
This recently triggered market signal has never failed to predict gains
Ophir Asset Management